These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 7905789)

  • 1. Elimination of CD4+ T cells in mice bearing an advanced sarcoma augments the antitumor action of interleukin-2.
    Rakhmilevich AL; North RJ
    Cancer Immunol Immunother; 1994 Feb; 38(2):107-12. PubMed ID: 7905789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transient depletion of CD4(+) T cells augments IL-21-based immunotherapy of disseminated neuroblastoma in syngeneic mice.
    Croce M; Corrias MV; Orengo AM; Brizzolara A; Carlini B; Borghi M; Rigo V; Pistoia V; Ferrini S
    Int J Cancer; 2010 Sep; 127(5):1141-50. PubMed ID: 20039320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
    Yoshizawa H; Chang AE; Shu SY
    Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes.
    Tanaka H; Tanaka J; Kjaergaard J; Shu S
    J Immunother; 2002; 25(3):207-17. PubMed ID: 12000862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
    Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
    Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curative effects of combination therapy with lentinan and interleukin-2 against established murine tumors, and the role of CD8-positive T cells.
    Suzuki M; Kikuchi T; Takatsuki F; Hamuro J
    Cancer Immunol Immunother; 1994 Jan; 38(1):1-8. PubMed ID: 8299113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.
    Jackaman C; Bundell CS; Kinnear BF; Smith AM; Filion P; van Hagen D; Robinson BW; Nelson DJ
    J Immunol; 2003 Nov; 171(10):5051-63. PubMed ID: 14607902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of donor specific transplantation tolerance to cardiac allografts following treatment with nondepleting (RIB 5/2) or depleting (OX-38) anti-CD4 mAb plus intrathymic or intravenous donor alloantigen.
    Arima T; Lehmann M; Flye MW
    Transplantation; 1997 Jan; 63(2):284-92. PubMed ID: 9020332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant IL-21 and anti-CD4 antibodies cooperate in syngeneic neuroblastoma immunotherapy and mediate long-lasting immunity.
    Rigo V; Corrias MV; Orengo AM; Brizzolara A; Emionite L; Fenoglio D; Filaci G; Croce M; Ferrini S
    Cancer Immunol Immunother; 2014 May; 63(5):501-11. PubMed ID: 24647609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure of anti-T cell monoclonal antibodies to prevent acute tumor allograft rejection is associated with their inability to deplete or inactivate T cells at the site of rejection.
    Rakhmilevich AL
    Transplantation; 1994 Jul; 58(1):72-80. PubMed ID: 7913562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of anti-tumor CD4+ T cell responsiveness in the tumor-bearing state and its recovery in in vitro culture free of tumor burden.
    Nagata T; Zou JP; Yamamoto N; Ono S; Fujiwara H; Hamaoka T
    Jpn J Cancer Res; 1993 Nov; 84(11):1181-9. PubMed ID: 7903964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of CD4(+) T cell help generates corrupt CD8(+) effector T cells in sarcoma-bearing Swiss mice treated with NLGP vaccine.
    Ghosh S; Sarkar M; Ghosh T; Guha I; Bhuniya A; Biswas J; Mallick A; Bose A; Baral R
    Immunol Lett; 2016 Jul; 175():31-9. PubMed ID: 27178306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-glycoprotein D monoclonal antibody protects against herpes simplex virus type 1-induced diseases in mice functionally depleted of selected T-cell subsets or asialo GM1+ cells.
    Staats HF; Oakes JE; Lausch RN
    J Virol; 1991 Nov; 65(11):6008-14. PubMed ID: 1920624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of T-cell subsets in the response to anti-CD3 monoclonal antibodies.
    Finck BK; Yung CM; Carteron NL; Wofsy D
    Clin Immunol Immunopathol; 1992 Dec; 65(3):234-41. PubMed ID: 1360341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CD3 + IL-2-stimulated murine killer cells. In vitro generation and in vivo antitumor activity.
    Anderson PM; Blazar BR; Bach FH; Ochoa AC
    J Immunol; 1989 Feb; 142(4):1383-94. PubMed ID: 2521662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.
    Shimizu J; Yamazaki S; Sakaguchi S
    J Immunol; 1999 Nov; 163(10):5211-8. PubMed ID: 10553041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo administration of IL-18 can induce IgE production through Th2 cytokine induction and up-regulation of CD40 ligand (CD154) expression on CD4+ T cells.
    Hoshino T; Yagita H; Ortaldo JR; Wiltrout RH; Young HA
    Eur J Immunol; 2000 Jul; 30(7):1998-2006. PubMed ID: 10940889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-specific CD4(+) suppressor T-cell clone capable of inhibiting rejection of syngeneic sarcoma in A/J mice.
    Fu T; Shen Y; Fujimoto S
    Int J Cancer; 2000 Sep; 87(5):680-7. PubMed ID: 10925362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence that long-term cardiac allograft survival induced by anti-CD4 monoclonal antibody does not require depletion of CD4+ T cells.
    Darby CR; Morris PJ; Wood KJ
    Transplantation; 1992 Sep; 54(3):483-90. PubMed ID: 1384184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cure of progressive murine leishmaniasis: interleukin 4 dominance is abolished by transient CD4(+) T cell depletion and T helper cell type 1-selective cytokine therapy.
    Heinzel FP; Rerko RM
    J Exp Med; 1999 Jun; 189(12):1895-906. PubMed ID: 10377185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.